ReviewTransplantation reviews (Orlando, Fla.)2011
The link between major histocompatibility complex antibodies and cell proliferation.
Review in Transplantation reviews (Orlando, Fla.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- CXCL16-driven CD4Journal for immunotherapy of cancer · 2026Article
- Transcriptomic signatures of chronic active antibody-mediated rejection deciphered by RNA sequencing of human kidney allografts.Kidney international · 2024Article
- Outside-in signaling through the major histocompatibility complex class-I cytoplasmic tail modulates glutamate receptor expression in neurons.Scientific reports · 2023Article
- Substratum interactions determine immune response to allogeneic transplants of endothelial cells.Frontiers in immunology · 2022Article
- Reverse Signaling by MHC-I Molecules in Immune and Non-Immune Cell Types.Frontiers in immunology · 2020Review
- MHC class I signaling: new functional perspectives for an old molecule.Tissue antigens · 2014Review
- Issues in solid-organ transplantation in children: translational research from bench to bedside.Clinics (Sao Paulo, Brazil) · 2014Review
- Allogenicity & immunogenicity in regenerative stem cell therapy.The Indian journal of medical research · 2013Article
- Role of complement and NK cells in antibody mediated rejection.Human immunology · 2012Review
- Heme oxygenase, inflammation, and fibrosis: the good, the bad, and the ugly?Frontiers in pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Experimental evidence indicates that donor-specific antibodies targeting major histocompatibility complex classes I and II molecules can elicit the key features of transplant vasculopathy by acting on the graft vasculature in 3 ways: directly activating proliferative, prosurvival, and migratory signaling in the target endothelial and smooth muscle cells; increasing expression of mitogenic factors in vascular endothelial cells, creating a potential proliferative autocrine loop; and promoting recruitment of inflammatory cells that produce mitogenic factors and elicit chronic inflammation, proliferation, and fibrosis. Here, we review the experimental literature showing the complement and Fc-independent effects of major histocompatibility complex classes I and II antibodies on graft vascular cells that may directly contribute to the proliferative aspect of transplant vasculopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.